|Mr. Ilan Ganot||Co-founder, Pres, CEO & Director||713.05k||N/A||1974|
|Mr. Matthew Bennett Arnold||Co-Founder & Independent Director||42.5k||N/A||1970|
|Ms. Annie Ganot||Co-Founder & Director of Patient Advocacy||N/A||N/A||N/A|
|Ms. Jennifer Ziolkowski CPA, CPA||CFO & Treasurer||N/A||N/A||1975|
|Dr. Joel Solomon Zev Schneider||Chief Technology Officer||N/A||N/A||1985|
Solid Biosciences Inc., a life science company, engages in identifying and developing therapies for duchenne muscular dystrophy (DMD) in the United States. The company's lead product candidate is SGT-001, an adeno-associated viral vector-mediated gene transfer, which is in a Phase I/II clinical trial to restore functional dystrophin protein expression in patients' muscles. Its portfolio also comprises Anti-LTBP4, a monoclonal antibody that is in preclinical trials to reduce fibrosis and inflammation. In addition, the company engages in developing biomarkers and sensors; and Solid Suit program that includes the development of wearable assistive devices that focus on providing functional and therapeutic benefits to DMD patients. Solid Biosciences Inc. was founded in 2013 and is headquartered in Cambridge, Massachusetts.
Solid Biosciences Inc.’s ISS Governance QualityScore as of December 9, 2019 is 9. The pillar scores are Audit: 10; Board: 9; Shareholder Rights: 8; Compensation: 7.